Ausgabe 5/2018
Inhalt (7 Artikel)
Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes (M Savona, Section Editor)
Aziz Nazha, Mrinal M. Patnaik
Updates on Circulating Tumor DNA Assessment in Lymphoma
- B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Justin M. Darrah, Alex F. Herrera
Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma
- B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Joanna Rhodes, Daniel J. Landsburg
Emerging EZH2 Inhibitors and Their Application in Lymphoma
- B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Jennifer K. Lue, Jennifer E. Amengual
Strategies for Predicting Response to Checkpoint Inhibitors
- CART and Immunotherapy (M Ruella, Section Editor)
Roberta Zappasodi, Jedd D. Wolchok, Taha Merghoub
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
- Acute Lymphocytic Leukemias (K Ballen and M Keng, Section Editors)
Katherine C. Pehlivan, Brynn B. Duncan, Daniel W. Lee
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis
- Myeloproliferative Neoplasms (B Stein, Section Editor)
John H. Baird, Jason Gotlib